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Preface 
This PhD thesis is based on research carried out in the Department of 
Environmental Engineering at the Technical University of Denmark from 
January 2015 to December 2017. It was prepared as part of the Mermiss 
project and performed under the main supervision of Professor Henrik 
Rasmus Andersen (DTU Environment) and the co-supervision of Professor 
Kai Bester (Aarhus University, Environmental Science). 
The thesis is organised in two parts: the first part puts into context the 
findings of the PhD in an introductive review, while the second consists of 
the papers listed below. These will be referred to in the text by their paper 
numbers, written with the Roman numerals I-V. 
 
I Ooi, G.T.H., Tang, K., Chhetri, R.K., Kaarsholm, K.M.S., 
Sundmark, K., Kragelund, C., Litty, K., Christensen, A., Lindholst, 
S., Sund, C., Christensson, M., Bester, K., Andersen, H.R., 2017. 
Biological treatment of hospital wastewater in a pilot-scale staged 
Moving Bed Biofilm Reactors (MBBRs) utilizing both nitrifying and 
denitrifying processes. Manuscript to be submitted.  
 
II Tang, K., Escola Casas, M., Ooi, G.T.H., Kaarsholm, K.M.S., 
Bester, K., Andersen, H.R., 2017. Influence of humic acid addition 
on the degradation of pharmaceuticals by biofilms in effluent 
wastewater. International Journal of Hygiene and Environmental 
Health, 220, 604-610. 
 
III Tang, K., Ooi, G.T.H., Litty, K., Sundmark, K., Kaarsholm, K.M.S., 
Sund, C., Kragelund, C., Christensson, M., Bester, K., Andersen, 
H.R., 2017. Removal of pharmaceuticals in conventionally treated 
wastewater by a polishing moving bed biofilm reactor (MBBR) with 
intermittent feeding. Bioresource Technology, 236, 77-86. 
 
IV Tang, K., Spiliotopoulou, A., Chhetri, R.K., Ooi, G.T.H., 
Kaarsholm, K.M.S., Sundmark, K., Florian, B., Kragelund, C., 
Bester, K., Andersen, H.R., 2017. Removal of pharmaceuticals, 
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toxicity and natural fluorescence by ozonation of biological treated 
hospital wastewater with further polishing by suspended biofilm. 
Manuscript to be submitted. 
 
V Tang, K., Ooi, G.T.H., Chhetri, R.K., Spiliotopoulou, A., 
Kaarsholm, K.M.S., Sundmark, K., Florian, B., Kragelund, C., 
Bester, K., Andersen, H.R., 2017. Removal of pharmaceuticals, 
toxicity and natural fluorescence by ozonation in biological pre-
treated municipal wastewater in comparison to subsequent polishing 
biofilm reactors. Manuscript to be submitted. 
In addition, the following publications, not included in this thesis, were also 
concluded during this PhD study: 
 Ooi, G.T.H., Tang, K., Bester, K., Andersen, H.R., 2017. Biological 
treatment of municipal wastewater in a pilot-scale staged Moving 
Bed Biofilm Reactors (MBBRs) and MBBRs combined with activat-
ed sludge (Hybas). Manuscript.  
 Tang, K., Kragelund, C., Andersen, H.R. (2017). Removal of phar-
maceuticals in conventionally treated wastewater by a polishing sand 
filtration with intermittent feeding. In preparation. 
 Droumpali, A., Tang, K., Litty, K., Mikkelsen, N., Lindholst, S., 
Kragelund, C., Andersen, H.R. (2017). Irrigation of treated 
wastewater in Samsø, Denmark. In preparation. 
Furthermore, this PhD study also contributed to several international confer-
ences with the following conferences papers: 
 Tang, K., Escola Casas, M., Bester, K., Andersen, H.R., Influence of     
dissolved organic carbon on biodegradation of pharmaceuticals by 
suspended biofilms in wastewater. 2
nd
 Young Water Professionals 
Denmark Conference and Workshop. Aarhus (Denmark), March 10-
11, 2016. Oral presentation.  
 Tang, K., Bester, K., Andersen, H.R., Polishing of pharmaceuticals 
in conventionally treated wastewater with intermittently fed Moving 
Bed Biofilm Reactors (MBBR). 8
th
 INTERNATIONAL WATER & 
HEALTH SEMINAR. Cannes (France), June 27-29, 2016. Oral 
presentation.  
 Tang, K., Ooi, G.T.H., Spiliotopoulou, A., Chhetri, R.K., Kaar-
sholm,       K.M.S., Florian, B., Kragelund, C., Bester, K., Andersen, 
H.R., Pharmaceuticals, toxicity and natural fluorescence intensity of 
v 
biologically treated hospital wastewater removed by pilot and labora-
tory scale ozonation. 15
th
 International Conference on Environmental 
Science and Technology. Rhodes (Greece), August 31 to September 
2, 2017. Oral Presentation.  
 Tang, K., Ooi, G.T.H., Litty, K., Sundmark, K., Sund, C., Krage-
lund, C., Christensson, M., Bester, K., Andersen, H.R., Removing re-
sidual pharmaceuticals from activated sludge effluent by intermit-
tently fed Moving Bed Biofilm Reactors (MBBR). 10
th
 Micropol & 
Ecohazard Conference. Vienna (Austria), September 18-20, 2017. 
Oral presentation.  
 Tang, K., Ooi, G.T.H., Florian, B., Sundmark, K., Sund, C., Krage-
lund, C., Bester, K., Andersen, H.R., Pilot and laboratory scale ozo-
nation of biologically treated hospital wastewater for removal of 
pharmaceuticals and toxicity concurrently with natural fluorescence 
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Summary 
Research on the removal of micropollutants (i.e. pharmaceuticals) has 
received a lot of attention in the last few decades. Wastewater treatment 
plants (WWTPs) act as the final checkpoint in controlling the quality of 
wastewater before discharge into receiving water. However, conventional 
WWTPs are not able to remove every pharmaceutical, including the majority 
of hardly biodegradable compounds and effluents that eventually affect the 
aquatic environment. Therefore, either upgrading traditional processes in 
WWTPs or the onsite treatment of pharmaceuticals at the point source (i.e. 
hospital wastewater), before release into the sewer system, must be 
considered, in order to overcome the above issues.  
Moving bed biofilm reactors (MBBRs) as an alternative to activated sludge 
have been already proven highly capable of removal of pharmaceutical. 
Based on 36 pharmaceuticals in hospital wastewater, the concentrations of 
which are limited through DHI (Institute for Water and Environment), these 
targeted compounds are investigated in this research despite no current 
regulations for the presence of pharmaceuticals WWTP effluent.  
Concentrations of substrate in wastewater can affect the degradation of 
organic micropollutants, due to a number of involved biodegradation 
mechanisms, including co-degradation and competitive inhibition. The effect 
of humic acid, as a model complex organic substrate, was investigated in 
relation to the biodegradation of pharmaceuticals in WWTP effluent via a 
laboratory-scale polishing MBBRs. Twelve investigated pharmaceuticals 
were significantly biodegradable. The biodegradation rate constants of ten of 
these compounds increased in line with increased humic acid concentrations, 
which shows that the presence of complex substrates stimulates degradation 
via a co-metabolism-like mechanism rather than competitive inhibition.  
Staged MBBRs were applied for polishing of the effluent of an activated 
sludge treatment plant, in order to enhance the removal of pharmaceuticals. 
To address the issue regarding effluent not containing sufficient organic 
matter to sustain enough biomass, a novel feeding approach, namely 
intermittent feeding to MBBRs reactor with WWTP effluent and settled raw 
wastewater, was implemented for the first time. First-order rate constants for 
pharmaceutical removal, normalized to biomass, were significantly higher 
compared to other studies on activated sludge and suspended biofilms, 
especially for diclofenac, metoprolol and atenolol. Due to intermittent 
x 
feeding, diclofenac degradation occurred with a half-life of only 2.1 hours 
and was thus much faster than any hitherto described wastewater bioreactor 
treatments. 
An onsite pilot-scale of staged MBBRs, involving only the MBBR technique, 
was applied to remove pharmaceuticals existing in raw hospital wastewater, 
in order to achieve relevant Danish regulation standards on discharge. 
Furthermore, a pilot-scale of staged MBBRs, involving MBBR and MBBR 
combined with activated sludge (Hybas) techniques, was applied to treat raw 
municipal wastewater, with the aim of attaining a high degree of 
pharmaceutical degradation. The strategy of intermittent feeding was carried 
out for both studies. In general, the majority of pharmaceuticals were 
removed sufficiently compared to other biological treatment processes, and 
the removal of diclofenac occurred in the reactors following the 
implementation of intermittent feeding.  
A pilot ozonation system was introduced to treat effluents from the staged 
MBBRs that were applied to treat hospital/municipal wastewater. This was 
able to attain further removal of remaining pharmaceuticals and toxicity. 
Concentrations of pharmaceuticals decreased when ozone dosage increased, 
and then the ozone dose reaching 90% removal of pharmaceutical was nor-
malized by DOC, following that relevant removal efficiency was comparable 
to literature studies of ozonation. Natural fluorescence as an easily measura-
ble parameter for the oxidation of organic matter in wastewater appeared to 
degrade quickly along with an increase in ozone doses. Microtoxicity in the 
wastewater of staged MBBRs decreased along the treatment train, and ozone 
was able to remove half of the remaining toxicity in MBBR effluents. Polish-
ing MBBRs applied after ozone, with the ultimate aim of reducing ozone by-
products, removed almost all water toxicity.   
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Dansk sammenfatning 
Forskning i fjernelse af mikroforureningsstoffer (f.eks. lægemidler) har fået 
stor opmærksomhed de seneste årtier. Spildevandsrensningsanlæg fungerer 
som den sidste barrier til at sikre kvaliteten af spildevand, før det udledes til 
recipienter. Konventionelle rensningsanlæg kan imidlertid ikke fjerne alle 
lægemidler, hvorved størstedelen af ikke-biologisk-nedbrydelige forbindelser 
udledes sammen med det behandlede spildevand, og de kan derved i sidste 
ende påvirker vandmiljøet. Derfor bør der enten ske en opgradering af tradi-
tionelle processer i rensningsanlæg eller en behandling af lægemidler ved 
kilden (dvs. behandling af hospitalsspildevand) inden udledning til kloaksy-
stemet. 
Moving Bed Biofilm Reactor (MBBR) som et alternativ til aktivt slam, har 
allerede vist sig at være i stand til at fjerne lægemidler. For 36 lægemidler er 
grænseværdier blevet foreslået i DHI (Institut for Vand og Miljø) til hospi-
talsaffald, på trods af manglende regler for tilstedeværelse af stoffer i kom-
munalt spildevand. 
Koncentrationer af co-substrat i spildevand kan påvirke nedbrydningen af 
organiske mikroforureningsstoffer på grund af forskellige bionedbrydnings-
mekanismer, herunder co-nedbrydning og konkurrencebetinget inhibering. 
Effekten af humussyre som modelstof for et komplekst organisk substrat, 
blev undersøgt i relation til biologisk nedbrydning af lægemidler i renset 
spildevand via en laboratorieskala MBBR biofilm. Tolv undersøgte lægemid-
ler var signifikant bionedbrydelige. De biologiske nedbrydningshastigheds-
konstanter for ti af disse lægemidler steg med øged koncentration af humus-
syre, hvilket viser at tilstedeværelsen af komplekse substrater stimulerer ned-
brydning via en co-metabolisme-lignende mekanisme snarere end konkurren-
cepræget inhibering. 
Trindelt MBBR blev anvendt til polering af spildevandet fra et aktivt slambe-
handlingsanlæg for at forbedre fjernelsen af lægemidler. For at løse proble-
met med at rense spildevand som ikke indeholder tilstrækkeligt organisk ma-
teriale til at opretholde tilfredsstillende biomasse, blev en ny fodringsmetode, 
nemlig intermitterende tilførsel af behandlet spildevand blandet med råt spil-
devand, implementeret for første gang. I biofilm dyrket på denne måde var 
førsteordenshastighedskonstanter for fjernelse af lægemidler, normaliseret til 
biomasse, signifikant højere sammenlignet med andre undersøgelser af aktivt 
slam og suspenderede biofilm, især for diclofenac, metoprolol og atenolol.  
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På grund af intermitterende fodring forekom diclofenac nedbrydning med en 
halveringstid på kun 2,1 timer hvilket var meget hurtigere end nogen tidligere 
beskrevne bioreaktorbehandling af spildevand. 
Et trindelt MBBR pilotskalaanlæg blev anvendt til at fjerne lægemidler i hos-
pitalsspildevand, for at opnå relevante danske reguleringsstandarder for ud-
ledning. Endvidere blev der anvendt et pilotanlæg med trindelt MBBR, der 
involverer MBBR og MBBR kombineret med aktivt slam (Hybas) til behand-
ling af råt kommunalt spildevand med det formål at opnå en høj grad af ned-
brydning af lægemidler. Strategien med intermitterende fodring blev udført 
for begge undersøgelser. Generelt blev størstedelen af lægemidlerne fjernet 
bedre sammenlignet med andre biologiske behandlingsprocesser, og fjernel-
sen af diclofenac forekom i reaktorerne efter implementeringen af intermitte-
rende fodring. 
Et pilot-ozoneringssystem blev opført til behandling af spildevand fra de 
trindelte MBBR'er, der blev anvendt til behandling af hospital/kommunalt 
spildevand. Dette var i stand til at opnå yderligere fjernelse af resterende læ-
gemidler og toksicitet. Koncentrationerne af lægemidler faldt med øget ozon-
doseringen. Den fundne DOC normaliseret ozondose, der er nødvendig for 
90% fjernelse af lægemiddel, var sammenlignelig med litteraturværdier for 
ozonering af behandlet spildevand. Naturlig fluorescens som en let målbar 
parameter for oxidation af organisk stof i spildevand, viste sig at nedbrydes 
hurtigt sammen med en stigning i ozon doser. Mikrotok® aktivitet i spilde-
vandet i den trindelte MBBR-anlæg faldt i takt med behandlingen, og ozon 
var i stand til at fjerne halvdelen af den resterende toksicitet i MBBR-
spildevandet. Polerende MBBR, som blev anvendt efter ozonbehandling med 
det formål at reducere ozonbiprodukter, fjernede næsten al toksiciteten. 
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1 Introduction 
1.1 Background and approach 
Due to the high consumption of pharmaceuticals in the last few decades, their 
widespread presence in wastewater has attracted a great deal of attention  
(Herrmann et al., 2015). However, conventional wastewater treatment plants 
(WWTPs) as the last obstacle were not able to completely degrade all phar-
maceuticals before discharging into receiving water sources (Verlicchi et al., 
2012b). Thus, contaminated WWTP effluent can affect the aquatic environ-
ment (Overturf et al., 2015). Consequently, moving bed biofilm reactors 
(MBBRs), as a recently biological technology, can be considered to address 
this issue (Ødegaard, 2006).  
MBBRs consist of flow-through wastewater and suspended plastic carriers, 
on which attached biofilms can grow. Previous studies have proven that 
MBBRs remove more pharmaceuticals than activated sludge (Escolà Casas et 
al., 2015a; Falås et al., 2012). To upgrade conventional WWTPs and enhance 
the chances of pharmaceutical removal, MBBRs can be used in two ways as 
an alternative to activated sludge. On the one hand, in order to partly or fully 
replace traditional wastewater treatment processes, MBBRs applied as onsite 
treatment solutions for hospital wastewater are able to ease the processing 
load for pharmaceutical removal for WWTPs, or fully municipal wastewater 
is received by MBBRs instead of activated sludge. On the other hand, 
MBBRs can be applied to polish WWTP effluent and thus remaining pharma-
ceuticals present in effluent wastewater are able to be further removed before 
discharge.  
For the first option, although MBBRs perform well in removing pharmaceuti-
cals, the polishing process is still demanded after MBBRs, and thus hardly 
biodegradable pharmaceuticals can be removed from MBBR effluent. Ozone, 
with matured experiences of operation and efficient cost, is considered as a 
feasible solution to polish effluent wastewater (Hansen et al., 2016; 
Hollender et al., 2009). However, ozone by-products with even higher toxici-
ty compared to original compounds cannot be avoided during ozone reaction. 
Besides examining removal of pharmaceutical via treatment processes, toxici-
ty in wastewater also needs be investigated, as it would clearly reveal the en-
tirely hazardous nature of wastewater and evaluate thoroughly the perfor-
mance of treatment processes. Furthermore, fluorescence technique, with ad-
vantages of rapid analysis and non-need for reagents, has been provided a 
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tool to monitoring of DOC fraction in wastewater and determine indirectly 
ozone in recirculating aquaculture systems water (Hudson et al., 2008; 
Spiliotopoulou et al., 2017). While, the knowledge gap, which addresses the 
correlation between fluorescence intensity and ozone dose in wastewater, 
need be understood. 
For the second aspect, WWTP effluent normally has a small amount of avail-
able carbon, and both biofilm growth and bacteria community certainly are 
related to the concentration and type of available carbon. As such, there is 
currently a lack of knowledge on how the available carbon affects the biodeg-
radation of pharmaceuticals by polishing MBBRs. Additionally, in the staged 
MBBRs, less activity in relation to pharmaceutical removal occurs in the last 
stage, due to the lack of sufficient carbon source to support biofilm growth. 
Therefore, to enhance the capacity of pharmaceutical removal in the last 
stage, along with improving the entire removal process in staged MBBRs, 
issues regarding the lack of sufficient biomass need be solved.  
1.2 Research aims 
This research is part of the Mermiss project that focuses mainly on address-
ing the issue of pharmaceutical removal in different types of wastewater, in-
cluding effluent in conventional WWTPs, raw hospital wastewater and mu-
nicipal wastewater. Degraders responsible for removing pharmaceuticals in 
wastewater have been identified as less active in the last stages of MBBRs 
and rely positively on available carbon source from the wastewater to support 
their growth. However, effluents or the last stage of MBBRs normally contain 
less carbon compared to raw wastewater and cannot provide sufficient carbon 
to promote degrader growth. To have more efficient degraders in MBBRs, 
and eventually to obtain a high degree of pharmaceutical removal, solutions 
need to be found to solve issues about the lack of carbon. Moreover, opti-
mised ozone dosages, applied in MBBR effluents to enhance the removal of 
non-biologically degradable compounds, need be understood as well. What’s 
more, the removal efficiency of compounds in MBBRs followed by ozone is 
not the only goal or index that needs attention, as toxicity development in 
ozonated wastewater should also be examined. A feasible and efficient pro-
cess that is able to reduce the relevant toxicity of ozonated wastewater before  
discharge ought to be considered.  
 
An overview of the approach used in this research is presented in Figure 1.1.  
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Figure 1.1. Overview of the research approach in this thesis.  
 
The detailed aims of this research are as follows: 
 Investigate the removal efficiency of pharmaceuticals in an onsite pilot of 
staged MBBRs, which was applied for treating hospital wastewater. Eval-
uate whether intermittent feeding to M3A/M3B with M2 effluent can en-
hance the removal of pharmaceuticals in M3. (Paper I) 
 Investigate the effect of an additional carbon source on the removal of 
pharmaceutical in effluent wastewater via a laboratory-scale MBBR. (Pa-
per II) 
 Evaluate whether intermittent feeding to a laboratory-scale polishing 
MBBR with raw settled wastewater and effluent wastewater will enhance 
the removal of pharmaceuticals in effluent wastewater. (Paper III) 
 Assess the effect of ozone dosage on the removal of pharmaceutical in 
MBBR effluent via pilot-scale and laboratory-scale ozone. The fluores-
cence intensity of ozonated wastewater for both the pilot and the laborato-
ry experiments was measured under specific wavelengths, and the toxicity 
of wastewater in the pilot treatment process, and ozonated wastewater, 
was investigated. (Paper IV) 
 Assess the effect of ozone dosage on the removal of pharmaceutical in 
MBBR effluent via pilot-scale and laboratory-scale ozone. The fluores-
cence intensity of ozonated wastewater for both the pilot and the laborato-
ry tests was measured under specific wavelengths, and the toxicity of 
wastewater in the pilot treatment process, and ozonated wastewater, was 
investigated. Also established whether a pilot-scale polishing MBBR ap-
4 
plied after ozonation will affect toxicity and fluorescence intensity. (Pa-
per V) 
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2 Pharmaceuticals in hospital/municipal 
wastewater, removed by a pilot-scale 
staged Moving Bed Biofilm Reactors 
(MBBRs) 
2.1 MBBRs system and experimental procedures 
A six staged pilot-scale MBBRs, receiving raw wastewater from University 
Hospital (Skejby, Denmark), was carried out to test the efficiency of remov-
ing pharmaceuticals. This MBBRs system includes six reactors in total under 
anaerobic and aerobic conditions (Figure 2.1, left). M1 with 900L and M4 
with 500L acted as denitrification reactors, while M2 and M3A/B with 900L, 
together with M5 with 500L, and were nitrification reactors. M1 and M4 re-
sponded to the removal of nitrate, and M5 was used as a polishing process for 
organic matter in denitrificated M4 effluent. The main task of M2 was to re-
move TOC, while pharmaceutical removal normally occurred in the M3A/B 
reactors during the nitrification processes. Based on the good pharmaceutical 
removal obtained from a novel strategy involving intermittent feeding to the 
reactors, and that this strategy was applied for the first time in this study, as 
described in Chapter 3, the feed flow from the M2 effluent to the third reactor 
(M3) was switched twice per day, in that either the flow went M3A first and 
then to M3B or the opposite way within 12 hours. Thus, biomass in the third 
reactor (M3A/B) would be promoted due to interchange feeding. The inlet 
flow rate and return flow rate were 800 L/h and 500 L/h, respectively.  
Additionally, the same staged pilot-scale MBBRs from above, albeit with a 
different treatment configuration was moved afterward to another place 
(Herning, Denmark) and raw municipal wastewater treated accordingly. Ra-
ther than the case where each reactor used in Skejby was a pure MBBR tech-
nique, the staged MBBRs applied at Herning consisted of a pure MBBR and a 
combination of MBBR and activated sludge (Hybas). Hence, this system, for 
denitrification, included an activated sludge reactor of 900 L (M1) and an 
MBBR reactor of 500 L (M4); however, for the nitrification process, it in-
cluded an activated sludge tank of 900 L (M2), Hybas reactors of 900 L 
(M3A and M3B) and a MBBR reactor of 500 L (M5) (Figure 2.2, left). In-
termittent feeding to M3A/B was also applied in this study. The inlet flow 
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rate, return flow rate and return sludge flow rates were 250 L/h, 500 L/h and 
300 L/h, respectively.  
 
Figure 2.1. Schematic diagram of a five-staged pilot-scale MBBR treatment train followed 
by pilot-scale ozonation (left). M0 stands for the hospital wastewater inlet. A lab-scale 
MBBR was used to polish ozonated effluent in the laboratory (right). (Paper IV) 
 
 
Figure 2.2. Schematic diagram of a five-stage pilot-scale MBBR treatment train followed 
by pilot-scale ozonation and an MBBR (left). M0 stands for the municipal wastewater in-
let. A lab-scale MBBR was used to polish ozonated effluent in the laboratory (right). (Pa-
per V) 
 
To test the capability of these two MBBRs systems on pharmaceutical re-
moval, batch experiments and continuous flow experiments were carried out. 
On the one hand, in the batch experiments, due to the need to spike the stock 
solution of pharmaceuticals in a realistic way, either carriers with the same 
filling ratios between the amount of carriers and the volume of wastewater or 
activated sludge, which depended on the individual treatment process of the 
reactor itself, were taken back to the laboratory, following which similar op-
erating conditions in field were simulated by using a resemble 3 L of reactor. 
Then, air pumps were used to create aerobic conditions, while nitrogen gas 
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was pumped into the reactor to maintain these anaerobic conditions. After 
spiking, samples were taken over time.  
On the other hand, in the continuous flow experiments, samples were taken 
from the influent and reactor effluent according to hydraulic retention time, 
and spiking would not execute because the actual behaviour of pharmaceuti-
cal removal in each reactor needed to be investigated in real-life conditions.   
2.2 Potential and actual capacity of pharmaceutical 
removals by MBBRs 
As the same experimental strategy was applied to both the hospital 
wastewater MBBRs (Skejby) and the municipal wastewater MBBRs (Hern-
ing), besides the differences in receiving wastewater and treatment processes 
applied for each reactor, the results for data treatment were similar, and 
therefore the following will focus only on experiments carried out with the 
hospital wastewater MBBRs as an exemplar. The targeted pharmaceuticals 
investigated in this study, as well as following studies, were classified into 
different groups: antibiotics (i.e. ciprofloxacin, sulfadiazine, sulfamethizole, 
trimethoprim, azithromycin and the sulfadiazine metabolite acetyl-
sulfadiazine), blood pressure regulators (i.e. atenolol, metoprolol, propranolol 
and sotalol), analgesics (i.e. carbamazepine, diclofenac, ibuprofen, phenazone 
and tramadol), antidepressants (i.e. venlafaxine) and X-ray contrast media 
(i.e. iopromide, iohexol and iopamidol). The details of pharmaceuticals in 
stock solution and relevant suppliers are presented in the Supplementary In-
formation of Paper II. Common parameters of wastewater in the Skejby 
MBBRs, along with months of operation, are illustrated in Table 2.1. The 
highest biomass was observed in the first denitrifying reactor (M2), due to 
sufficient carbon in the relevant influent, and yet the biomass in M3A and 
M3B was identical because of interchangeable feeding to these two reactors 
with M2 effluent for an equal amount of time. Almost 90% of TOC was re-
moved by the MBBRs and a high level of NH4
+–N and NO2
- 
-N was removed 
as well, which indicates good nitrification and denitrification achieved 
through MBBRs treatment.  
For the batch experiments, the concentrations of analysed pharmaceuticals 
over time were plotted based on first-order kinetics (2.1), and six representa-
tive compounds are presented in Figure 2.3.  
kteCC  0  (2.1) 
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Table 2.1. Common parameters of wastewater in the Skejby staged MBBRs. (Paper I) 
Reactor HRT Biofilm pH DO TOC NH4
+–N NO2
-–N NO3
-–N 
 [h] [g/L]  [mgO/L] [mgC/L] [mgN/L] [mgN/L] [mgN/L] 
Influent   7.9±0.3 2.6±1.7 137±45 49.3±14.2 0.06±0.0 0.6±0.2 
M1 1.13 2.84 7.9±0.3 0.5±0.1 55±32 30.5±13.7 0.06±0.0 0.7±0.3 
M2 1.13 5.13 7.8±0.2 4.9±2.4 16±3 19.5±13.1  0.4±0.0 
M3A 1.13 3.23 7.7±0.3 6.8±2.4 18±6 5.4±6.6  12.3±6.8 
M3B 1.13 3.23 7.6±0.3 5.7±3.1 19±10 4.8±7.2  13.7±4.2 
M4 1.67 2.45 7.8±0.3 0.6±0.4 17±4 6.5±8.8 0.24±0.2 0.9±0.7 
M5 1.67 3.33 8.0±0.2 7.1±2.7 16±3 4.3±7.7  2.3±0.4 
 
In general, the higher level of pharmaceutical removal occurred in the nitrify-
ing MBBRs (M2, M3 and M5) as opposed to the denitrifying MBBRs and the 
fast degradation of pharmaceuticals was observed in M3A/B. However, for 
trimethoprim, high removal levels were found in the denitrifying MBBRs ra-
ther than the nitrifying MBBRs. Additionally, and based on the fitting results 
of first-order kinetics, the degradation rate constant (k) of each pharmaceuti-
cal was obtained (Table 2.2). The highest k values were often found in M2 
and M3A/B, namely, the majority of pharmaceuticals were degraded in these 
two nitrifying reactors.  
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 Figure 2.3. First-order reaction rate fitting to concentrations of selected pharmaceuticals 
in batch experiments. The dashed horizontal line stands for the limit of quantification 
(LOQ) as derived from the lower of two multiple reaction monitoring (MRM) signals. 
(Paper I) 
 
For the continuous flow experiments, Figure 2.4a shows an overview of how 
much was removed from each reactor, while the entire MBBRs removal for 
from influent to effluent is illustrated in Figure 2.4b. The M5 reactor general-
ly removed a major amount of pharmaceuticals despite low carbon levels 
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compared with other front reactors. It was assumed that biofilms need to uti-
lise the hardly carbon or even the energy produced by the transformation of 
pharmaceuticals to support their growth. Detected compounds above LOQs 
normally achieved more than 50% removal. Diclofenac, known as a hardly 
biodegradable compound (Joss et al., 2006), achieved 80% removal. Howev-
er, the average removal of diclofenac in the activated sludge and membrane 
bioreactor (MBR) was 36% and 48%, respectively (Vieno and Sillanpää, 
2014). In Figure 2.4a, the negative removal of sulfamethizole and sulfameth-
oxazole happened in the first MBBR reactors (i.e. M1). This phenomenon 
could be explained due to conjugated compounds derived from sulfame-
thizole and sulfamethoxazole attaching to a sulfo group, an acetyl group or a 
glucuroic acid component (Berger et al., 2008). Furthermore, in the presence 
of relevant bacterial enzymes in wastewater, the de-conjugation process oc-
curs, and thus conjugated compounds de-conjugate with respective groups 
and transform back to sulfamethizole or sulfamethoxazole. 
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Figure 2.4. a) An overview of the removal contribution of each reactor; b) an overview of 
the entire removal from influent to effluent. (Paper I) 
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Table 2.2. Removal rate constant, ki, of pharmaceuticals in each reactor. (Modified version from Paper I) 
Compounds 
M1 M2 M3A/M3B M4 M5 
kM1 [h
-1
] r
2
 kM2 [h
-1
] r
2
 kM3 [h
-1
] r
2
 kM4 [h
-1
] r
2
 kM5 [h
-1
] r
2
 
Acetyl-sulfadiazine 19.2±5.2 ×10
-2 
0.92 11.7±1.3 ×10
-1 
0.99 9.1±2.1 ×10
-1 
0.97 21.9±1.9 ×10
-2 
0.99 11.6±1.4 ×10
-2 
0.99 
Atenolol 11.8±4.4 ×10
-3 
0.69 48.5±3.1 ×10
-2 
1.00 7.9±1.4 ×10
-1 
0.98 23.0±2.3 ×10
-2 
0.99 28.4±2.0 ×10
-2 
1.00 
Azithromycin 12.5±4.5 ×10
-2 
0.85 5.7±5.1 ×10
-1 
0.30 6.0±4.3 ×10
-2 
0.53 4.8±1.3 ×10
-1 
0.96 25.1±2.9 ×10
-3 
0.97 
Carbamazepine 6.3±7.1 ×10
-3 
0.17 5.5±17.4 ×10
-3 
0.03 1.4±1.5 ×10
-2 
0.26 2.5±5.5 ×10
-3 
0.06 49.7±9.8 ×10
-4 
0.90 
Ciprofloxacin 1.3±0.0 ×10
-16 
0.00 1.5±3.0 ×10
-2 
0.06 8.1±15.9 ×10
-3 
0.08 1.7±0.0 ×10
-16 
0.00 9.6±7.2 ×10
-3 
0.40 
Clarithromycin 11.0±4.2 ×10
-2 
0.85 44.6±5.1 ×10
-2 
0.99 5.3±2.2 ×10
-1 
0.90 49.8±2.9 ×10
-2 
1.00 71.7±6.2 ×10
-3 
0.99 
Diatrizoic acid 2.2±0.0 ×10
-16 
0.00 2.68±157 ×10
-4 
0.00 9.5±14.1 ×10
-3 
0.13 10.1±3.7 ×10
-3 
0.73 2.8±2.8 ×10
-3 
0.26 
Diclofenac 1.7±0.0 ×10
-16 
0.00 7.1±0.0 ×10
-14 
0.00 2.4±1.2 ×10
-2 
0.64 3.4±8.1 ×10
-3 
0.05 1.5±0.0 ×10
-16 
0.00 
Ibuprofen 1.1±1.6 ×10
-2 
0.14 2.6±1.1 ×10
0 
0.97 21.0±8.2 ×10
-1 
0.95 7.7±1.3 ×10
-2 
0.97 81.5±9.2 ×10
-2 
0.99 
Iohexol 1.3±0.0 ×10
-16 
0.00 22.5±1.9 ×10
-2 
1.00 111±8 ×10
-2 
1.00 67.7±8.7 ×10
-4 
0.96 166±4 ×10
-3 
1.00 
Iomeprol 1.7±0.0 ×10
-16 
0.00 18.4±1.6 ×10
-2 
0.99 76.8±8.2 ×10
-2 
1.00 6.0±5.8 ×10
-3 
0.27 11.3±1.1 ×10
-2 
0.99 
Iopamidol 2.3±2.3 ×10
-3 
0.21 2.04±168 ×10
-4 
0.00 2.0±1.5 ×10
-2 
0.43 4.1±2.2 ×10
-3 
0.54 4.5±2.0 ×10
-3 
0.64 
Iopromide 4.2±2.2 ×10
-1 
0.42 4.4±1.1 ×10
-1 
0.97 14.8±4.2 ×10
-1 
0.96 9.2±4.5 ×10
-3 
0.61 19.6±4.5 ×10
-2 
0.96 
Metoprolol 2.2±0.0 ×10
-16 
0.00 11.6±3.1 ×10
-2 
0.92 8.9±3.7 ×10
-2 
0.83 2.7±3.7 ×10
-3 
0.16 15.1±2.8 ×10
-3 
0.92 
Phenazone 1.8±0.0 ×10
-16 
0.00 24.9±6.7 ×10
-2 
0.94 5.1±2.6 ×10
-2 
0.67 1.5±0.0 ×10
-16 
0.00 5.1±1.5 ×10
-3 
0.79 
Propranolol 3.7±2.2 ×10
-2 
0.47 2.6±2.3 ×10
-1 
0.25 3.4±2.9 ×10
-2 
0.36 3.0±1.6 ×10
-2 
0.59 1.4±1.3 ×10
-2 
0.29 
Sotalol 1.6±2.2 ×10
-3 
0.12 6.9±3.0 ×10
-2 
0.74 4.3±2.4 ×10
-2 
0.62 1.4±2.0 ×10
-3 
0.14 189±8 ×10
-4 
1.00 
Sulfadiazine 1.7±0.0 ×10
-16 
0.00 2.6±1.6 ×10
-2 
0.51 16.6±4.6 ×10
-2 
0.94 1.9±0.0 ×10
-16 
0.00 34.3±4.5×10
-2 
0.99 
Sulfamethizole 2.9±2.4 ×10
-2 
0.29 12.6±4.7 ×10
-2 
0.85 9.7±2.6 ×10
-1 
0.96 10.0±7.8 ×10
-3 
0.36 69±3 ×10
-2 
1.00 
Sulfamethoxazole 7.3±9.5 ×10
-3 
0.15 3.8±2.3 ×10
-2 
0.52 21.0±6.5 ×10
-2 
0.93 17.6±2.8 ×10
-3 
0.94 3.6±1.0 ×10
-1 
0.94 
Trimethoprim 39.8±5.1 ×10
-2 
0.98 2.3±3.2 ×10
-2 
0.14 4.4±1.9 ×10
-2 
0.74 4.7±1.2 ×10
-2 
0.89 19.2±2.0 ×10
-3 
0.97 
Venlafaxine 1.7±0.0 ×10
-16 
0.00 3.2±2.6 ×10
-2 
0.35 2.4±2.4 ×10
-2 
0.29 9.5±2.8 ×10
-3 
0.81 5.0±4.9 ×10
-3 
0.26 
2.3 Comparison of rate constants normalised by biomass 
To evaluate the differences in performance relating to pharmaceutical removal, between the currently staged MBBRs and 
other bioreactor treatment studies, the rate constant of pharmaceuticals in each reactor was normalised to the correspond-
ing biomass in the respective reactor, and thus kbio was calculated (Table 2.3). High kbio values, namely the most efficient 
biofilm responsible for pharmaceutical removal, were also observed in M3, which was according to the results of rate con-
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stants of pharmaceuticals obtained from batch experiments and further strengthened the novel strategy that the intermittent 
feeding to reactors fully was applicable even at the pilot stage.  
Table 2.3. Removal rate constant normalised with biomass, kbio,i, of pharmaceuticals in each reactor. (Modified version from Paper I) 
Compounds kbio, M1 [L h
-1
 g
-1
] kbio, M2 [L h
-1
 g
-1
] kbio, M3 [L h
-1
 g
-1
] kbio, M4 [L h
-1
 g
-1
] kbio, M5 [L h
-1
 g
-1
] Literature Ref
1
 Conditions 
Acetyl-sulfadiazine 6.76 × 10
-2
 2.28 × 10
-1
 2.81 × 10
-1
 8.94 × 10
-2
 3.48 × 10
-2
    
      2.79−3.75 × 10-2 A NMBBR 
Azithromycin 4.40 × 10
-2
 1.11 × 10
-1
 1.86 × 10
-2
 1.96 × 10
-1
 7.54 × 10
-3
    
      ≤4.17 × 10-3 A NMBBR 
Ciprofloxacin 4.68 × 10
-17
 2.83 × 10
-3
 2.49 × 10
-3
 7.10 × 10
-17
 2.88 × 10
-3
    
      7.50−12.1 × 10-3 A NMBBR 
Diatrizoic acid 7.82 × 10
-17
 5.22 × 10
-5
 2.95 × 10
-3
 4.12 × 10
-3
 8.38 × 10
-4
    
Diclofenac 6.06 × 10
-17
 1.38 × 10
-14
 7.49 × 10
-3
 1.37 × 10
-3
 4.35 × 10
-17
 ≤4.17 × 10-3 A DNAS 
<1.67 × 10
-3 
B DNAS 
4.17 × 10
-3 
C DNAS 
Ibuprofen 3.98 × 10
-3
 5.13 × 10
-1
 6.50 × 10
-1
 3.16 × 10
-2
 2.45 × 10
-1
 6.25 × 10
-2
 B DNAS 
0.00−6.46 × 10-1 D NMBBR 
Iohexol 4.72 × 10
-17
 4.39 × 10
-2
 3.44 × 10
-1
 2.76 × 10
-3
 4.98 × 10
-2
    
Iomeprol 5.92 × 10
-17
 3.59 × 10
-2
 2.38 × 10
-1
 2.44 × 10
-3
 3.39 × 10
-2
    
Iopamidol 8.13 × 10
-4
 3.98 × 10
-5
 6.32 × 10
-3
 1.67 × 10
-3
 1.34 × 10
-3
    
Iopromide 1.49 × 10
-1
 8.58 × 10
-2
 4.58 × 10
-1
 3.74 × 10
-3
 5.89 × 10
-2
    
      2.88−3.17 × 10-2 A NMBBR 
      ≤4.17 × 10-3 A NMBBR 
Propranolol 1.30 × 10
-2
 5.01 × 10
-2
 1.04 × 10
-2
 1.23 × 10
-2
 4.29 × 10
-3
    
Sotalol 5.60 × 10
-4
 1.35 × 10
-2
 1.33 × 10
-2
 5.59 × 10
-4
 5.68 × 10
-3
    
Sulfadiazine 5.88 × 10
-17
 4.99 × 10
-3
 5.14 × 10
-2
 7.92 × 10
-17
 1.03 × 10
-1
    
Sulfamethizole 1.01 × 10
-2
 2.46 × 10
-2
 3.01 × 10
-1
 4.08 × 10
-3
 2.07 × 10
-1
    
      6.25−8.33 × 10
-3
 A NMBBR 
Ref
1
: A=Falås et al., (2013) (rate constants: L h
-1
 gTS
-1
); B=Suarez et al., (2010) (rate constants: L h
-1
 gVSS
-1
); C=Plósz et al., (2012) (rate con-
stants: L h
-1
 gTSS
-1
); D=Falås et al., (2012) (rate constants: L h
-1
 gTS
-1
). DNAS: Denitrifying Activated Sludge; NMBBR: Nitrifying MBBR.  
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3 Pharmaceuticals in municipal effluent, 
removed by a laboratory-scale MBBRs 
3.1 Influence of humic acid addition on the removal 
of pharmaceuticals 
3.1.1 Experimental procedures 
The characteristics of bacteria from biomass in wastewater have been found 
to be related to and affected by the conditions in which they grow (Cydzik-
Kwiatkowska and Zielińska, 2016). Among various wastewater parameters 
ensuring living conditions for bacterial growth, the concentration and catego-
ry of the carbon source play a vital role. Mechanisms for the biodegradation 
of pharmaceuticals in the presence of organic carbon can be classified in two 
ways: co-metabolism and competitive inhibition.  
Co-metabolism involves the transformation of a non-growth substrate (i.e. 
micropollutants) while a growth substrate (i.e. available carbon source) ex-
ists. Previous studies have found that the biodegradation of 4-chlorophenol, 
considered a non-growth substrate, is enhanced when introducing primary 
growth substrates, for instance phenol and glucose (Tobajas et al., 2012). 
However, for competitive inhibition, although the growth substrate is a pre-
requisite for the degradation of a non-growth substrate, the bacterial enzymes 
which are responsible for non-growth substrate biodegradation may interact 
with the growth substrate as a kind of competitor, and thus the biodegradation 
rate of the non-growth substrate is inhibited and decreases. Joss et al. (2004) 
found that differences in the removal rates of oestrogens, between the batch 
experiment and the corresponding compartment of full-scale plants, could be 
interpreted in terms of the competitive inhibition of oestrogen degradation by 
the substrate. 
In this study, humic acid (HA), considered a not easily degradable carbon 
source, was used to simulate different concentrations of complex carbon 
sources in wastewater. A laboratory-scale MBBRs mimicked a polishing step 
for WWTP effluent. The experiments were performed in Erlenmeyer flasks 
containing spiked pharmaceuticals, MBBR carriers and WWTP effluent, with 
or without the addition of HA (blank). A 10 μL pharmaceutical stock solution 
was transferred to each flask, which had initial concentrations of pharmaceu-
ticals ranging from 1.2 and 14.6 μg/L. MBBR carriers with attached biofilm 
fed by wastewater effluent for three months were placed into each flask, and 
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the filling ratios of the carriers and wastewater volume were constant. Three 
differently defined concentrations of HA were applied and thus gave dis-
solved organic carbon in quantities of 4.4, 11, 13 and 30 mgC/L. The Erlen-
meyer flasks were placed on a mechanical shaker (120 rpm) for a period of 
two weeks, and samples were taken over time. Details of the methods em-
ployed, common wastewater parameters and pharmaceutical analysis are de-
scribed in paper II.  
3.1.2 Influence of humic acid on pharmaceutical degradation 
MBBR carriers in each flask had 2.5 g/L of biomass, which was lower than 
the values observed from previous studies, where around 3.1 g/L was ob-
tained (Falås et al., 2013). This can be explained by the fact that the carriers 
used in this study were fed by wastewater effluent containing very little car-
bon utilised for biofilm growth.  
The development of pharmaceutical concentrations with different HA dosag-
es over time was plotted by first-order kinetics (Equation 2.1). All investigat-
ed compounds are presented in Figure 3.1. Thirteen out of the 22 detected 
pharmaceuticals were recognised as being biodegradable by biofilm, because 
the differences in pharmaceutical concentrations between the controlled ex-
periments (new carriers without biofilm) and the comparative experiments 
(with attached biofilm) were clear when increasing DOC by adding HA. Spe-
cifically, there was low or no activity in relation to the removal of pharma-
ceuticals in the control experiment compared to the high extent of pharma-
ceutical removal in the comparative experiments. For the remaining pharma-
ceuticals (nine out of 22), they were considered to belong to the non-
biodegradable group. This definition can be interpreted in two ways. First, 
several compounds (phenanzone, sulfadiazine, sulfamethoxazole, tramadol 
and venlafaxine) were not removed in either the controlled or the compara-
tive experiments. For the second aspect, other compounds (azithromycin, 
clarithromycin, erythromycin, roxithromycin), in relation to the development 
of pharmaceutical concentrations, did not differ statistically from the con-
trolled or comparative experiments. Therefore, the 13 biodegradable com-
pounds above, which showed the influence of adding HA on the removal of 
pharmaceuticals, were selected and are discussed in the following sections.  
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Figure 3.1. Normalised concentration of pharmaceuticals with initial values fitted by first-
order kinetics (Equation 2.1) in batch incubations of MBBR carriers under different initial 
DOCs. The legend shows the measured initial DOC concentrations. Controls were flasks 
using new carriers (without biofilm). Error bar indicates standard deviation (Paper II). 
 
For these biodegradable compounds, an overview regarding the rate constant 
of each compound under different DOC concentrations is presented in Figure 
3.2. There was a positive correlation between rate constant and DOC values 
(HA concentration), the higher rate constant along with a higher DOC. There-
fore, we can assume co-metabolism acted as the main interaction mechanism 
between the biodegradation of pharmaceuticals and the addition of HA as an 
extra carbon source. Otherwise, if a competitive mechanism were involved, 
the results in Figure 3.2 were opposite. Due to the continuous shaking of the 
flasks during the experiments, this study replicated aeration conditions. Tran 
et. al (2013) also found pharmaceuticals were oxidised during the microbial 
metabolism of another growth substrate in aeration conditions. 
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Figure 3.2. Rate constants (k) of pharmaceuticals in the batch incubations of MBBR carr i-
ers under different initial DOCs. Control stands for flasks containing carriers without bio-
film. Control flasks contained also 4.4 mgC/L of DOC. N.A. indicates that the concentra-
tion curve did not fit to Equation 2.1. Error bar indicates standard deviation (Paper II). 
 
3.1.3 Correlation of total concentration of organic matter and rate 
constant 
The statistical results for the correlation of the rate constants of 13 biode-
gradable pharmaceuticals, and the initial DOC values, are presented in Table 
3.1, based on the first-order kinetics fitting results taken from Figure 3.2. Ten 
out of the 13 compounds (except carbamazepine, ibuprofen and sulfame-
thizole) had high or very high R
2
, indicating that the addition of HA had 
stimulated the pharmaceutical biodegradation. Calculating the difference of 
rate constants in high DOC (30 mgC/L) and low DOC (4.4 mgC/L), normal-
ised with the relevant DOC difference, the average stimulation for all biode-
gradable pharmaceuticals was 7.4% per mgC/L, and the 25%, 50% and 75% 
percentiles were 2.8, 6.4 and 8.7% per mgC/L, respectively (Figure 3.3). Be-
sides, the values of the rate constant in high DOC normally were two or three 
times higher than the values obtained from the controlled experiment (with-
out biofilm).  
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Table 3.1. Removal rate constant, ki, and the correlation between rate constants and initial 
DOC. The correlation between the parameters expressed as R
2
 is categorised as VH (very 
high) H (high correlation) M (moderate correlation and L (low correlation) according to 
the criteria in Asuero et al. (2006) (Paper II). 
 
Figure 3.3. Plot of all the removal rate constants (k) obtained by single-fitting first-order 
kinetics (Equation 2.1) to the concentrations of all biodegradable pharmaceuticals in the 
batch incubations of MBBR carriers versus different initial DOCs. Error bar indicates 
standard deviation (Paper II). 
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0
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4.0×10 -3
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Iohexol Iomeprol
DOC (mgC/L)
k
 (
h
-1
)
Compound 
4.4 mgC/L DOC 11 mgC/L DOC 13 mgC/L DOC 30 mgC/L DOC Rate constant vs DOC 
kHA0 (h
-1
) kHA1 (h
-1
) kHA2 (h
-1
) kHA3 (h
-1
) 
Slope 
(L·mgC
-1
·h
-1
) 
R
2
 Corr. 
Ac-Sulfadiazine 3.8±0.9·10
-3
 1.2±0.3·10
-3
 8±1·10
-3
 9±0.8·10
-3
 2.3·10
-4
 0.50 H 
Atenolol 6.3±0.5·10
-3
 3.7±0.2·10
-3
 8.4±0.8·10
-3
 11.2±1·10
-3
 2.3·10
-4
 0.61 H 
Carba-mazepine 2.1±0.3·10
-3
 1.3±0.3·10
-3
 1.9±2·10
-3
 1.7±0.6·10
-3
 (-)5.6·10
-6
 0.03 L 
Citalopram 4.6±3.6·10
-4
 6.4±2.1·10
-4
 1.4±0.2·10
-3
 3.7±1.6·10
-3
 1.31·10
-4
 0.96 VH 
Diclofenac 0.6±0.1·10
-3
 1.0·10
-16
 5.0±2·10
-3
 2.2±0.8·10
-3
 0.7·10
-4
 0.74 H 
Ibuprofen 61±10·10
-3
 56±3·10
-3
 50±1·10
-3
 60±10·10
-3
 1.2·10
-4
 0.12 L 
Iohexol 0.9±0.3·10
-3
 0.2±0.2·10
-3
 1.8±0.2·10
-3
 2.4±0.7·10
-3
 0.7·10
-4
 0.58 H 
Iomeprol 0.5±0.2·10
-3
 0.1±0.3·10
-3
 0.9±0.2·10
-3
 1.5±0.2·10
-3
 0.5·10
-4
 0.69 H 
Iopromide 1.4±0.4·10
-3
 0.8±0.4·10
-3
 2.4±0.4·10
-3
 3.8±0.3·10
-3
 1.1·10
-4
 0.77 H 
Metoprolol 2.4±0.4·10
-3
 3.0±2·10
-3
 6±1·10
-3
 11±4·10
-3
 3.6·10
-4
 0.95 VH 
Propranolol 4.6±0.3·0
-3
 3.6±0.4·10
-3
 5±1·10
-3
 12±2·10
-3
 3.4·10
-4
 0.87 VH 
Sotalol 1.8±0.3·10
-3
 1.2±0.2·10
-3
 2±0.1·10
-3
 2.4±0.1·10
-3
 0.3·10
-4
 0.54 H 
Sulfa-methizole 0.8±0.3·10
-3
 0.3±0.3·10
-3
 1.5±0.4·10
-3
 1.3±0.3·10
-3
 0.3·10
-4
 0.28 M 
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3.2 Removal of pharmaceuticals by an 
intermittently fed polishing MBBRs 
3.2.1 MBBRs system and experimental methods 
Since conventional WWTPS (i.e. activated sludge) are not able to remove all 
micropollutants from wastewater, some micropollutants, such as pharmaceu-
ticals, are well-known as persistent compounds that remain detectable in 
WWTP effluent (Verlicchi et al., 2012a, 2012b). Therefore, polishing treat-
ments for WWTP effluent need be carried out to upgrade and improve the 
quality of effluent, in order to achieve discharge standards. In previous stud-
ies, MBBRs have been used to demonstrate that most pharmaceuticals can be 
degraded to some extent and with better removal efficiency compared to acti-
vated sludge (Escolà Casas et al., 2015a). However, for refractor compounds 
(i.e. diclofenac), their remove rates are still low and result in poor water qual-
ity. For diclofenac, as one of three crucial compounds in the first watch list 
authority set up by the European Commission (Carvalho et al., 2015), its deg-
radation rate when treated  with current wastewater purification processes is 
not optimistic. Thus, it is an urgent undertaking to find a solution to this is-
sue.  
A previous MBBR study was conducted by three pilot-scale static-staged 
MBBRs fed by raw hospital wastewater (Escolà Casas et al., 2015a). Hence, 
the first reactor in this treatment train had more nutrients for biofilm growth 
compared to the two following reactors. The last reactor particularly had to 
utilise hardly degradable nutrients from the second reactor’s effluent, to sup-
port biofilm activity, where mostly the thinnest biofilm was observed in the 
last reactor as well as the thickness of biofilm or the amount of biomass de-
cay from the first reactor to the last reactor. Based on kbio of diclofenac in the 
last reactor from a former MBBR study, although the removal degree of di-
clofenac was low, this reactor degrader was capable of degrading diclofenac 
did exist, and the reason for ineffective removal could be explained by a lack 
of biomass. Then, to improve the overall removal of diclofenac by staged 
MBBRs, the removal control in the last reactor was very important, since this 
reactor acted as the last line of defence against pharmaceuticals before dis-
charging the effluent. To elevate the amount of degrader in the last reactor, 
the primary task is to achieve an amount of biomass sufficient enough to 
eventually benefit degrader growth.  
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Thus, in this study, MBBRs were used for polishing wastewater effluent from 
a conventional WWTP in Denmark and to overcome inactive biomass genera-
tion in the last reactor, due to low substrate concentration. For the first time, 
we carried out a programme of intermittent feeding to MBBR reactors with 
raw wastewater from a primary settling tank, and WWTP effluent. The de-
scription for the above feeding strategy is illustrated in Figure 3.4. Essential-
ly, three identical 3 L reactors with 50% filling ratio of carriers were used. A 
two-stage MBBR treatment train (reactors 1 and 2 in positions A and B; Fig-
ure 3.4a) was fed with CAS effluent and performed as a polishing reactor. 
Another MBBR treatment train with a single reactor (reactor 3 in position C) 
was fed with settled raw wastewater, which we used to stimulate biomass 
generation as a regenerated reactor. After two days of operation, the feeding 
of reactors in these two MBBR treatment trains was changed, and thus reactor 
3 was placed in position A and fed with CAS effluent, reactor 1 was then 
moved to Position B and reactor 2 was switched to position C to operate as a 
regeneration reactor (Figure 3.4b). Following a further two days, the feeding 
programme was changed again, as outlined above. This was followed by an-
other three days of operation before changing the next feeding regime so that 
the reactors returned back to their initial positions, as presented in Figure 
3.4a. This feeding strategy was conducted three times per week. 
 
Figure 3.4. Configuration of the MBBR system: (a) Operation of a two-stage MBBR 
treatment train polishing effluent water from the Viby WWTP (positions A and B), while 
the growth of biofilm was stimulated in another MBBR treatment train with a single reac-
21 
tor (position C). (b) The change of feeding to two MBBR treatment trains was conducted 
three times per week. (Paper III) 
3.2.2 Performance of intermittently fed MBBRs on wastewater 
parameters 
To ensure the non-static polishing MBBR system remained stable, common 
wastewater parameters were measured during the four-month operating peri-
od (Table 3.2).  
Table 3.2. Common wastewater parameters of reactors in three positions in an MBBR over 
a long time period (13/04/2015-24/08/2015). Indicated intervals (±) are standard deviation 
of means. DO: Dissolved oxygen, DOC: dissolved organic carbon. (Paper III) 
Reactor HRT 
(h) 
pH DO 
(mg·L
-1
) 
DOC 
(mg·L
-1
) 
NH4
+
-N 
(mg·L
-1
) 
CAS effluent  7.4±0.1  8.2±1.3 0.84±0.44 
Position A 0.5 7.7±0.5 7.2±0.9 8.1±1.2 0.16±0.10 
Position B 0.5 8.0±0.5 8.3±0.9 8.7±2.1 0.04±0.04 
Settled raw wastewater  7.6±0.1  22±5.0 24±5 
Position C  7.8±0.5 7.4±1.4 9.1±1.6 0.28±0.16 
 
‘CAS effluent’ represents effluents from the full-scale WWTP, and ‘settled 
raw wastewater’ stands for wastewater taken from the primary settler which 
was used for feeding the reactor in position C. In this intermittently fed sys-
tem, concentrations of NH4
+
-N from influent to effluent were almost removed 
totally, which demonstrates this MBBR system had good nitrification ability. 
This phenomenon, on the other hand, is also supported by the dissolved oxy-
gen concentration (DO) in each reactor at above 2 mg·L
-1
,
 
which was re-
quired for processing aeration reactions. The average biomass in positions A, 
B and C during the period 13/04/15 to 24/08/2015 were 1.3±0.2, 1.1±0.2 and 
1.0±0.2 g·L
-1
, respectively. Therefore, biomass was considered identical in 
all three reactors, which agrees with the fact that there is not enough time in 
positions A and B to lose significant amounts of biomass, due to the rapid 
changing of the reactor feed patterns.  
3.2.3 Biodegradation of pharmaceuticals in the MBBRs 
To test the potential capacity of pharmaceutical removal by intermittently fed 
MBBR systems, a batch experiment was conducted. During this experiment, 
the water flow of influent and in between reactors was stopped and a stock 
solution of pharmaceuticals was spiked into each reactor, which gave the ini-
tial concentration of pharmaceuticals at around 3-20 µg·L
-1 
(Figure 3.5a). 
Then, samples were taken from each reactor over time. However, to test the 
actual performance of intermittently fed MBBR systems in real life, a contin-
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uous flow experiment was conducted. In this experiment, the water flow was 
allowed to travel through the systems without stopping or spiking (Figure 
3.5b). Samples were taken from the influent and reactor effluents according 
to hydraulic retention time (HRT). 
 
Figure 3.5. Configuration of the staged MBBR during the batch and continuous flow ex-
periments: (a) the batch experiments were carried out to measure the biofilms’ capacity to 
degrade pharmaceuticals, and the flow was discontinued while concentrations of spiked 
pharmaceuticals were measured over time. (b) During the continuous flow experiment. 
(Paper III) 
 
For the batch experiment, pharmaceutical concentrations over time were plot-
ted and fitted with first-order kinetics and are presented in Figure 3.6. Apply-
ing first-order kinetics to describe the development of pharmaceutical con-
centration was feasible, since most of the pharmaceuticals were able to obtain 
good R
2 
values (>0.96), except for propranolol, tramadol and venlafaxine, 
and similar findings were also observed in a previous study (Escolà Casas et 
al., 2015b). In Figure 3.6, all of the investigated pharmaceuticals, except car-
bamazepine, defined as a recalcitrantly biodegradable compound (Joss et al., 
2006), demonstrated the potential to be biodegradable to some degree. In 
terms of diclofenac, its half-life was around 2.1 h, and within 12 h it could be 
removed entirely, which was faster than any biological treatment processes 
examined so far.  
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Acetyl-sulfadiazine is a conjugation product formed through the human me-
tabolism of sulfadiazine; however, rapid de-conjugation usually occurs 
through relevant microorganisms in wastewater, which eventually transfer 
back to sulfadiazine again. Therefore, in this study, in the first five hours of 
reaction, the concentration of sulfadiazine increased due to the contribution 
of the de-conjugation of ac-sulfadiazine, and so the concentration of ac-
sulfadiazine decreased and moved gradually closer to zero within the first 
five hours. After five hours, sulfadiazine concentration started to decrease 
until the last sampling time, while ac-sulfadiazine was barely detected and 
therefore no longer contributed. Kovalova et al. (2012) also found the similar 
reactions for other compounds in the sulphonamides group.  
 
Figure 3.6. First-order reaction rate fitting to concentrations of pharmaceuticals (except 
sulfadiazine) in batch experiments (reactor in position A, fed by CAS effluent, and then 
effluent from position A flows into the reactor in position B. However, the reactor in pos i-
tion C is fed by settled raw wastewater. Before starting the spiking experiment, the flow of 
each reactor was stopped). The dashed horizontal line stands for the limit of quant ification 
(LOQ), as derived from the lower of two multiple reaction monitoring (MRM) signals. 
(Paper III) 
 
In Table 3.3, the rate constant (k) and kbio of pharmaceuticals in this study are 
compared to three similar MBBR studies. For the kbio of intermittently fed 
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reactors in this study, eight out of 15 pharmaceuticals (i.e. atenolol, ciprof-
loxacin, diclofenac, iopromide, metoprolol, sulfamethizole, tramadol and 
venlafaxine) for reactors in positions A and B increased in comparison to the 
static staged reactors (Escolà Casas et al., 2015a, 2015b). In terms of diclo-
fenac, kbio in this study was ten times higher or even more than its values ob-
tained from previous researches. Thus, the amount of degrader response to 
degrade diclofenac was promoted through the novel intermittent feeding con-
cept.  
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Table 3.3 Comparison of rate constants (k, h
-1
) and biomass normalised rate constants (kbio, L·h
-1
·g
-1
). (Paper III) 
                                k (h
-1
) kbio (L·h
-1
·g
-1
) 
Compound 
This experiment 
Effluent polishing of suspended 
biofilm 
(This experiment)
 Staged MBBR WWTP 
(a) 
 Effluent 
polishing 
MBBR 
(b)
 
Biofilm in 
IFAS 
WWTP 
(c)
 Position A Position B Position C Position A Position B Position C Stage 1 Stage 2 Stage 3 
Ac-
Sulfadia-
zine 41±1·10
-2
 57±1·10
-2
 33±1·10
-2
 34·10
-2
 39·10
-2
 24·10
-2
 35·10
-2
 77·10
-2
 3.8·10
-2
 1.1·10
-2
 
 Atenolol 32±1·10
-2
 43±1·10
-2
 19±1·10
-2
 26·10
-2
 29·10
-2
 13·10
-2
 8.2·10
-2
 18·10
-2
 14·10
-2
 5.0·10
-2
 2.5·10
-2
 
Ciprofloxa-
cin 79±17·10
-2
 119±19·10
-2
 201±22·10
-2
 65·10
-2
 80·10
-2
 146·10
-2
 0.3·10
-2
 0.8·10
-2
 2.1·10
-2
 
  Diclofenac 28±1·10
-2
 33±1·10
-2
 32±1·10
-2
 23·10
-2
 22·10
-2
 23·10
-2
 2.6·10
-2
 5.7·10
-2
 1.5·10
-2
 0.3·10
-2
 6.3·10
-2
 
Ibuprofen 313±13·10
-2
 433±6·10
-2
 181±7·10
-2
 258·10
-2
 291·10
-2
 131·10
-2
 131·10
-2
 291·10
-2
 48·10
-2
 
  Iopromide 0.7±0.1·10
-2
 3.1±0.2·10
-2
 1.9±0.1·10
-2
 0.6·10
-2
 2.1·10
-2
 1.4·10
-2
 0.3·10
-2
 0.7·10
-2
 2.0·10
-2
 0.7·10
-2
 
 Metoprolol 25±1·10
-2
 28±1·10
-2
 12±1·10
-2
 21·10
-2
 19·10
-2
 8.7·10
-2
 2.3·10
-2
 5.2·10
-2
 3.0·10
-2
 1.0·10
-2
 1.1·10
-2
 
Phenanzon
e 1.1±0.1·10
-2
 1.0±0.1·10
-2
 1.5±0.1·10
-2
 0.9·10
-2
 0.7·10
-2
 1.1·10
-2
 0.9·10
-2
 1.9·10
-2
 3.6·10
-2
 0.6·10
-2
 0.4·10
-2
 
Propranolol 77±24·10
-2
 77±26·10
-2
 22±6·10
-2
 64·10
-2
 52·10
-2
 16·10
-2
 76·10
-2
 169·10
-2
 13·10
-2
 2.1·10
-2
 
 Sotalol 2.8±0.1·10
-2
 4.9±0.1·10
-2
 1.9±0.1·10
-2
 2.3·10
-2
 3.3·10
-2
 1.4·10
-2
 2.6·10
-2
 5.8·10
-2
 3.1·10
-2
 1.0·10
-2
 
 Sulfame-
thizole 5.3±0.2·10
-2
 14±1·10
-2
 8.8±0.7·10
-2
 4.3·10
-2
 9.2·10
-2
 6.4·10
-2
 1.0·10
-2
 2.1·10
-2
 2.9·10
-2
 0.9·10
-2
 
 Sulfameth-
oxazole 1.2±0.0·10
-2
 1.7±0.1·10
-2
 2.2±0.0·10
-2
 1.0·10
-2
 1.1·10
-2
 1.6·10
-2
 0.8·10
-2
 1.8·10
-2
 1.1·10
-2
 0.4·10
-2
 
 Tramadol 2.0±1.0·10
-2
 2.2±0.6·10
-2
 2.0±0.2·10
-2
 1.6·10
-2
 1.5·10
-2
 1.5·10
-2
 0.4·10
-2
 0.8·10
-2
 0.5·10
-2
 0.6·10
-2
 
 Trime-
thoprim 2.0±0.1·10
-2
 1.7±0.1·10
-2
 2.0±0.1·10
-2
 1.7·10
-2
 1.1·10
-2
 1.4·10
-2
 2.8·10
-2
 6.3·10
-2
 2.9·10
-2
 1.1·10
-2
 9.0·10
-2
 
Venlafaxine 2.3±0.7·10
-2
 2.0±0.6·10
-2
 1.8±0.2·10
-2
 1.9·10
-2
 1.4·10
-2
 1.3·10
-2
 0.4·10
-2
 0.9·10
-2
 1.5·10
-2
 0.6·10
-2
 0.4·10
-2 
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(a): a three-stage MBBR system (reactors 1, 2 and 3) fed by wastewater from the oncology 
section of Aarhus University Hospital (Escolà Casas et al., 2015a). 
(b): one-stage MBBR (reactor H4) which was a polishing process after treatment with act i-
vated sludge combined with MBBR (Hybas) (also fed by wastewater from the oncology 
section of Århus University Hospital) (Escolà Casas et al., 2015b).  
(c): One-stage IFAS (integrated fixed-film activated sludge, reactor M) stands for a 10 L 
reactor filled with wastewater and carriers from a domestic WWTP in Switzerland (Falås et 
al., 2013). 
 
Additionally, similar results can also be found for sulfamethizole (an antibi-
otic). The kbio in positions A and B, especially position B, was significantly 
higher than in the three reactors from the statically staged MBBR (Escolà 
Casas et al., 2015a). 
For continuous flow experiments, natural concentrations of pharmaceuticals 
without spiking were analysed in influent and the reactors’ effluent (Figure 
3.7). In reality, diclofenac concentration decreased from influent to effluent, 
which in turn confirmed the potential biodegradability seen in the batch ex-
periment. Furthermore, the removal of pharmaceuticals increased in line with 
an increase in HRT; for instance, atenolol was totally degraded when HRT 
increased from 1 h to 4 h, and the removal of metoprolol increased from 7% 
to 69%, while the removal of propranolol increased from 3% to 43%. For sul-
famethizole, removal changed from negative to 48 %. 
 
Figure 3.7. Concentrations of selected pharmaceuticals in continuous experiments with 
different HRTs. The dashed horizontal lines indicate the LOQ for each pharmaceutical , 
derived from two multiple reaction monitoring (MRM) transitions. (Paper III) 
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4 Pharmaceuticals in the effluent of a 
pilot-scale staged MBBRs treated by 
ozone and followed with a polishing 
MBBR 
4.1 MBBRs/ozone system and experimental 
methods 
Although MBBRs are better at removing pharmaceuticals compared to CAS, 
and thus may be considered as an alternative for conventional treatment pro-
cesses applied in most WWTPs, some hardly biodegradable pharmaceuticals 
were still be detected in MBBRs effluents, as mentioned in Chapter 2, such as 
X-ray contrast medias, venlafaxine, carbamazepine and so on.  
To address this issue, ozone, known with matured implement experiences to 
balance the sufficient removal of pharmaceuticals and operation expenses,  is 
a feasible technology, using as a polishing method to enhance pharmaceutical 
removal (Hansen et al., 2016; Ternes et al., 2003). The oxidation of pharma-
ceuticals by ozonation results in two vital paths: a direct reaction with certain 
functional groups of organic molecules (4.1) and an indirect/non-selective 
reaction with strong oxidant hydroxyl radicals (4.2) (Dantas et al., 2007).  
OX3 ROR                      (4.1) 
OXROHR                    (4.2) 
In this study, pilot-scale ozone setups, mainly consisting of an ozone genera-
tor and an ozone reaction column, were applied for polishing effluents from 
two pilot-scale staged MBBRs receiving either raw hospital wastewater (Ske-
jby, Denmark) or municipal wastewater (Herning, Denmark), as described in 
Chapter 2 as well. The HRT for the ozone setup connected with the staged 
MBBR treating hospital wastewater was 13.1 min, based on a 1 L/min flow 
rate of ozone influent and a 13 L column volume. A schematic diagram of the 
treatment configuration can be found in Figure 2.1(right).  
However, the HRT for the ozone setup connected with the staged MBBR 
treating municipal wastewater was 9 min, according to a 2 L/min influent 
flow rate and an 18 L reactor. Furthermore, in order to purify and reduce fur-
ther the effluent toxicity generated from ozone by-products, a pilot-scale 
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MBBR with a HRT of 14 min was applied for polishing ozonation effluent. A 
description of the treatment configuration is illustrated in Figure 2.2 (right). 
For performance tests of both of the polishing methods above, first, to opti-
mise the dosage of ozone to obtain high pharmaceutical removal efficiency, 
different doses were applied into the reaction column. Furthermore, to verify 
pharmaceutical removal by ozonation, the same MBBR effluents were taken 
back to the laboratory and ozonation experiments carried out in a laboratory-
scale ozone setup with similar ozone doses. Meanwhile, the fluorescence in-
tensity of both ozonated wastewaters in the pilot and laboratory tests was 
measured under six selected wavelengths. Second, toxicity development in 
the wastewater in line with the treatment configurations in the pilot were 
measured, and a toxicity test of MBBRs effluents treated with laboratory-
scale ozonation followed by a polishing MBBR were also conducted.  
To determine the ozone dosage that achieved 90% removal of each pharma-
ceutical in the effluent, the correlation of degradation rate of each pharma-
ceutical and ozone dosage was fitted by equation (4.3).  
  
)
DDO
DO
(
0
3
3
10
C
C 
   (4.3) 
The remaining concentration of pharmaceutical (C) is related to its initial 
concentration (C0) after a relevant reaction with a specific delivered ozone 
dose (DO3) with a decadic dose of ozone (DDO3), as the compound-specific 
constant describing the required ozone dosage needed to remove 90% of the 
respective pharmaceutical. This was based on the fact that that the decay of 
ozone is determined by the effluent matrix and is independent of pharmaceu-
tical concentration. 
4.2 Removal of pharmaceuticals 
Normalised concentrations of pharmaceuticals with different doses of ozone 
were plotted according to the above equation (4.3). Twenty-two pharmaceuti-
cals were detected in the effluent of the pre-treating MBBRs for hospital 
wastewater without spiking, while 15 out of 22 compounds were above LOQs 
(Figure 4.1). However, for effluents from the pre-treating MBBRs for munic-
ipal wastewater, 24 pharmaceuticals were detected, while 21 out of 24 com-
pounds were above relevant LOQs (Figure 4.2).  
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Figure 4.1. Comparison of pharmaceutical removal by ozone in the effluent of the staged 
MBBR demonstration plant at Skejby Hospital, using the onsite continuous pilot ozonation 
system and batch treatment in the laboratory. The dashed lines in the figure stand for the 
limit of quantification (LOQ) of pharmaceuticals by HPLC-MS/MS. Error bars represent 
standard deviations. (Paper IV) 
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Figure 4.2. Comparison of pharmaceutical removal by ozone in the effluent of the staged 
MBBR demonstration plant at the Herning municipal treatment plant, using the onsite con-
tinuous pilot ozonation system and batch treatment in the laboratory. The dashed lines in 
the figure stand for the limit of quantification (LOQ) of pharmaceuticals by HPLC-
MS/MS. Error bars represent standard deviations. (Paper V) 
 
In general, concentrations of pharmaceuticals above LOQs decreased in line 
with an increase in ozone dose in both MBBR effluent-polished studies. 
Nonetheless, iohexol, iopamidol and iopromide from the contrast media 
group were barely removed, even with high ozone concentrations. To evalu-
ate pharmaceutical removal efficiency, the DDO3 of individual pharmaceuti-
cals was obtained, based on the fitting curve established from equation (4.3). 
When comparing the DDO3 of each pharmaceutical from one pilot experiment 
to another, or one laboratory experiment to another or between pilot and la-
boratory experiments, they were not identical. Many factors could explain 
these different results, for instance HRT, ozone setups, wastewater substrate 
and so on. Among these factors, DOC as a critical water substrate parameter 
is able to affect significantly the performance of the ozonation process 
(Blaney, 2014). Thus, to make the results of this study more accurate and 
comparable with other similar studies, the DDO3 of each pharmaceutical was 
normalised to effluent DOC and thus Z90 was calculated (Table 4.1). 
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Table 4.1. Ozone dosage for 90% removal of pharmaceuticals in the pilot and laboratory and the normalisation of ozone dosage to the relevant 
DOC condition (Z90=DDO3/DOC, DOC of this study is 40 mg O3/L). Indicated intervals represent one standard deviation. (Paper IV) 
  Pilot Laboratory Z90 
          DDO3 R
2
      DDO3 R
2
      Pilot          Laboratory A B 
Ac-sulfadiazine <LOQ
a
 <LOQ 
      
Atenolol 103±19 0.89 46±7 0.91 2.6±0.5 1.1±0.2 
 
1.1 
characterizeAzithromycin <LOQ <LOQ <LOQ <LOQ 
    
Carbamazepine 147±53
c
 0.63 7.4±1.1 0.96 3.7±1.3 0.18±0.03 0.61 0.58 
Ciprofloxacin <LOQ <LOQ <LOQ <LOQ 
    
Clarithromycin <LOQ <LOQ 39±6 0.92 
 
0.98±0.14 
 
0.75 
Diatrizoic acid <LOQ <LOQ <LOQ <LOQ 
   
4.7 
Ibuprofen <LOQ <LOQ 46±8 0.78 
 
1.1±0.2 1.61 1.3 
Iohexol 151±42 0.77 110±30 0.69 3.8±1.0 2.7±0.7 
 
1.8 
Iomeprol No fit
b
 0.41 No fit 0.44 
   
1.9 
Iopamidol No fit 0.01 No fit 0.34 
   
2.6 
Iopromide  <LOQ <LOQ 
      
Metoprolol 52±6 0.94 54±10 0.75 1.3±0.2 1.3±0.2 1 0.89 
Phenazone <LOQ <LOQ <LOQ <LOQ 
   
0.77 
Propranolol 42±9 0.79 35±2 0.96 1.0±0.2 0.88±0.06 
 
0.6 
Sotalol <LOQ <LOQ <LOQ <LOQ 
    
Sulfadiazine  <LOQ <LOQ 
     
0.5 
Sulfamethizole 50±12 0.862 <LOQ <LOQ 1.2±0.03 
 
0.77 0.52 
Sulfamethoxazole 56±9 0.74 68±14 0.66 1.4±0.2 1.7±0.3 
 
0.52 
Tramadol 33±19 0.64 31±9 0.77 0.81±0.47 0.8±0.2 
 
0.97 
Trimethoprim 51±12 0.61 29±2 0.96 1.3±0.3 0.73±0.06 0.55 0.55 
Venlafaxine 44±7 0.90 50±9 0.77 1.1±0.2 1.2±0.2 0.91 1.4 
a: If concentration is below the limit of quantification (LOQ), it indicates <LOQ.  
b: If R2 <0.5, it indicates no fit. 
c: If 0.5<R2 <0.7, it is considered a poor fit and indicates Italic. 
A indicates the reference (Antoniou et al., 2013).  
B indicates the reference (Hansen et al., 2016).  
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Antoniou et al. (2013) investigated the influence of different effluent matri-
ces on the removal of spiked pharmaceuticals through laboratory ozonation, 
while Hansen et al. (2016) studied the effect of DOC on the removal of 
spiked pharmaceuticals in effluent from a staged MBBR with laboratory 
ozone equipment, finding that the obtained Z90 values from effluent with dif-
ferent DOCs were comparable. When comparing the Z90 of the current two 
studies with previous similar researches, corresponding Z90 values apply to 
clarithromycin, ibuprofen, iomeprol, iopamidol, metoprolol, sulfamethizole, 
trimethoprim and venlafaxine. Based on these findings, we may consider that 
Z90 can be used as an index to evaluate the efficient removal of pharmaceuti-
cal by ozonation.  
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4.3 Removal of natural fluorescence indicators 
Fluorescence can be used as a tracer for the source fraction of DOC and its 
transformation during ozonation (Hudson, Naomi; Baker, Andy; Reynolds, 
2007). Previous research has indicated that fluorescence can be used as a 
monitoring tool to determine indirectly ozone in recirculating aquaculture 
system water (Spiliotopoulou et al., 2017). The detailed introductions regard-
ing fluorescence and the specific wavelengths used in this study are described 
in Papers IV and V.  
Hence, the same ozonated samples from the pilot and laboratory experiments 
with different ozone doses were measured in six fluorescence wavelengths, 
consisting of protein-like and humic-like fluorophores (Figure 4.3).  
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Figure 4.3. (a)-(d): comparison of remaining natural fluorescence of MBBRs effluent 
treated by ozone, using the pilot or laboratory method. (Paper IV) 
 
Generally, if looking at the trend of fluorescence intensity in these two stud-
ies, the intensity of both the protein and the humic-like fluorophores de-
creased in line with an increase in ozone concentration. This decreasing fluo-
rescence intensity can be explained by the depletion of or variation in aro-
matic structures and the increase of electron withdrawing groups such as 
COOH in aromatic compounds (Świetlik and Sikorska, 2004). In the pilot 
Herning study, the intensity of all protein-like fluorescent peaks decreased 
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significantly with ozone dosages around 2-10 mg O3/L, whereas, for the la-
boratory experiments, the intensity of all protein-like fluorescence peaks de-
creased gradually and ended up at about 40 mg O3/L. However, the intensity 
of humic-like fluorescent could not be removed in all instances, even at high 
ozone concentrations (40 or 50 mg O3/L), because humic-like fluorescence 
stands for the least degradable organic matter in wastewater. Similar experi-
mental findings regarding changes on the fluorescence intensity of protein-
like and humic-like fluorophores were also observed in the Skejby experi-
ments. Therefore, in order to predict and control water quality in online sys-
tems, less ozone is required when aiming at removing protein-like fluores-
cence, while high levels of ozone are needed when looking to remove humic-
like fluorescence.  
Additionally, in the Herning experiments, when investigating the develop-
ment of fluorescence intensity over time in the wastewater treated in the la-
boratory through ozone and a polishing MBBR, the results were different 
compared with the standalone ozone process (Figure 4.4).  
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Figure 4.4. Development of natural fluorescence of MBBRs effluent treated by a single 
polishing MBBR, four doses of ozone in the laboratory, with or without subsequent MBBR 
polishing. (Paper V) 
 
Normally, MBBRs effluent polishing with ozone and a subsequent MBBR 
can bring fluorescence intensity down to great extent compared to ozone 
treatment only. When increasing the contact time between ozonated 
wastewater and the subsequent MBBR, the relevant fluorescence intensity 
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gradually decreased. However, for humic-like fluorescent, the intensity of 
ozonated wastewater with a subsequent MBBR slowly increased until termi-
nation of the experiment, because during the MBBR polishing process, the 
attached biofilm started to detach and eventually dissolved in the wastewater, 
thereby contributing some fluorescence intensity. Overall, based on this la-
boratory test, ozone followed by a polishing MBBR is able to purify 
wastewater further and improve the quality of any discharge into receiving 
water.  
4.4 Performance of micro-toxicity 
Microtoxicity tests at 15 min of exposure time were carried out to investigate 
wastewater characteristics for the Herning staged MBBRs process and onsite 
continuous ozonation (Figure 4.5). Basically, the inhibition of toxicity was 
reduced on a tank by tank basis. The inhibitions of toxicity in ozonated 
wastewater first decreased and then increased again in both studies when 
ozone dosage increased. In this case, we can assume that highly toxic ozone 
by-products, compared to original substances, gradually generated when in-
creasing ozone up to high concentrations. However, low concentrations of 
ozone were able to reduce half of the toxicity from MBBRs effluent.  
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Figure 4.5. Toxicity measured with a MicroTox® test with 15 min exposure time in a pi-
lot-scale MBBR treatment train (a) and onsite continuous pilot ozonation (b). M0: munici-
pal influent fed into the pilot-scale MBBR treatment train. RF: return flow from M3B, 
marked with a black circle. RS: return sludge flow from a settling tank after M3B, marked 
with a blue triangle. M5: effluent from the MBBR treatment train, which was also the ini-
tial inlet for ozonation (O3 =0 mg/L). (Paper V) 
 
In the Herning study, a pilot polishing MBBR was applied in order to purify 
the ozonation effluent further. A comparison of toxicity inhibition between 
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ozonated wastewater and ozonated wastewater with a polishing MBBR is 
presented in Figure 4.6. In Figure 4.6a, the MBBR effluent was treated with 
different concentrations of ozone followed by a pilot polishing MBBR. Inhi-
bitions decreased in line with increasing ozone concentrations, from 2 to 4 
mg O3/L, while they increased again when the applied ozone concentration 
reached 8 to 12 mg O3/L, before gradually decreasing from 15 to 30 mg O3/L. 
In the first stage, toxic DOC in ozonated effluent was reduced when increas-
ing ozone concentration, while in the second stage, DOC was gradually re-
duced down close to zero. Simultaneously, ozone by-products were the main 
source of toxicity, and so the higher amount of ozone applied in the effluent, 
the higher the toxic ozone by-products produced, which led to an increase in 
inhibition. In the last stage, with ozone concentrations, inhibition decreased 
again, due to existing ozone by-products removed by a sufficient amount of 
ozone. For each ozone concentration applied, the subsequent polishing 
MBBR was able to bring down the remaining toxicity in ozonated effluent to 
almost zero, indicating that polishing MBBRs offer a very important and effi-
cient way of enhancing the purification of ozonated effluent. 
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Figure 4.6. Comparison of MicroTox® with 15 min exposure time with different concen-
trations of ozone from the pilot and the laboratory experiments, followed by relevant pilot-
scale or lab-scale MBBR polishing over time. (a) Staged MBBR effluent treated by onsite 
continuous pilot-scale ozone with various doses and a subsequent pilot MBBR polishing 
tank, (b) staged MBBR effluent treated by eight doses of ozone in the laboratory, (c) 
wastewater effluent treated by a single polishing MBBR, four doses of ozone in the labora-
tory, with or without subsequent MBBR polishing. (Paper V) 
 
To understand further the features of microtoxicity development in ozonated 
wastewater, with or without polishing MBBR afterwards, the same MBBR 
effluent was ozonated with various doses in the laboratory, and the inhibition 
of individually ozonated samples decreased over time (Figure 4.6b). Over a 
2-hour ozone reaction time, the inhibition of ozonated samples first decreased 
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and then increased when ozone concentration increased, which fitted to the 
first and second stages mentioned above. In Figure 4.6c, MBBR effluent was 
treated with different concentrations of ozone followed with a polishing 
MBBR in the laboratory. Over 2 hours’ contact time, each ozonated sample 
treated with a polishing MBBR was less inhibited compared to the ozone-
only samples, which again verified that the polishing MBBR is able to reduce 
further the toxicity of ozonated effluent. 
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5 Conclusions  
The main findings of this thesis can be concluded as follow: 
A pilot-scale staged MBBRs with both denitrification and nitrification pro-
cesses, was proven as a feasible and effective solution to easing the effects of 
hospital wastewater on the environment. On the one hand, general parameters 
of wastewater, such as TOC, NH4
+–N and NO2
-
-N, were removed to a high 
extent, and thus this onsite MBBRs system was able to reduce treatment load-
ing in conventional WWTPs, as the treated MBBRs effluents eventually dis-
charge into the municipal sewer system. On the other hand, the higher kbio of 
the majority of pharmaceuticals was observed for either denitrification or ni-
trification when compared to other similar researches on activated sludge and 
MBBRs. More than 50% of pharmaceuticals above LOQ in continuous flow 
experiments were removed. For diclofenac as a refractory compound, through 
intermittent feeding into the M3A/B reactors, its removal at 80% was two 
times higher compared to average removal in activated sludge or MBR.   
Humic acid, simulating an externally complex carbon source, can affect the 
biodegradation rates of pharmaceutical in effluent treated by a laboratory-
scale polishing MBBR as a tertiary treatment process. Twelve out of 24 in-
vestigated pharmaceuticals discovered as biodegradable compounds degraded 
faster with an increase in TOC derived from humic acid addition, thereby in-
dicating that co-metabolism plays an important role, rather than competitive 
mechanisms, during pharmaceutical biodegradation. Similar conclusions have 
also been reached in previous research, where pharmaceuticals were oxidised 
by an enzyme or a co-factor produced during the metabolism of another 
growth substrate. The average stimulation of the first-order rate constant for 
biodegradable pharmaceuticals was 5% per mg DOC. 30 mgC/L by humic 
acid addition enhanced about three times the biodegradation performance of 
the laboratory-scale MBBRs. 
By implementing the intermittent feeding of laboratory-scale MBBR reactors 
with raw settled wastewater and WWTP effluent for the first time, not only 
can MBBRs purify wastewater in relation to the high removal of ammonia, 
but degraders with the ability to biodegrade diclofenac present in wastewater 
are also promoted through an increase in biomass. Thus, the 2.1 h half-life of 
diclofenac, discovered in the intermittent feeding MBBRs system, was short-
er than any wastewater bioreactor treatments to date, and its kbio was more 
than ten times higher than in other similar studies. Moreover, for beta blocker 
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compounds such as those found in atenolol and metoprolol, their kbio was also 
significantly higher compared to previous studies.  
Ozonation was a feasible enforcement method for polishing the effluent of 
staged MBBRs and most pharmaceuticals remaining in MBBR effluent were 
removed when increasing ozone levels. Z90, deriving from the normalisation 
of ozone doses with DOC, was used as a measuring index to compare the re-
moval efficiency of pharmaceuticals in different ozonation experiments, and 
it can be considered to evaluate ozone performance for pharmaceutical re-
moval. Fluorescence intensity, positively relating to BOD in wastewater, can 
also be considered as an index of water quality when using ozonation to puri-
fy wastewater. Based on experimental results, less ozone was needed when 
looking to reduce the fluorescence intensity of protein-like fluorophores; 
however, high amounts of ozone were required when reducing the fluores-
cence intensity of humic-like fluorophores. Pilot-scale staged MBBRs were 
capable of reducing toxicity inhibitions in wastewater, reactor by reactor, and 
subsequent ozone further reduced by half any toxicity remaining in MBBRs 
effluent. A polishing MBBR as a tertiary treatment solution, conjugated with 
ozone, was used to purify ozone effluent, and its toxicity caused by ozone by-
products was entirely removed. Accordingly, ozonated wastewater treated 
with the polishing MBBR afterwards generally had the lowest intensity of 
protein-like fluorescence.  
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6 Future perspectives 
The issue of a lack of sufficient biomass in effluents was addressed for the 
first time through the novel approach, which is intermittent feeding to labora-
tory-scale MBBRs with raw settled wastewater and WWTP effluent. There-
fore, diclofenac a hardly degradable compound in effluent has achieved a 
half-time of degradation shorter than resulting from other biological reactors. 
Then, if the experimental methodology were scaled up from the laboratory to 
full scale, where the conditions and matrices of wastewater are much more 
complicated, it’s interesting to know whether short half-life time of diclo-
fenac can be still achieved or not if the novel feeding approach above could 
carry out in a full scale polishing MBBR.   
In this study, an on-site pilot of staged MBBRs was carried out to treat raw 
hospital wastewater, and generally it was able to remove investigated phar-
maceuticals to a high degree along with an overall reduction in wastewater 
toxicity. Implementing an on-site MBBR to treat wastewater, resulting in 
ease further loading process of WWTPs, can also be promote to treat other 
types of wastewater (i.e. wastewater in pharmaceutical factory) rather than 
only hospital wastewater in this study. 
Natural fluorescence intensity in wastewater is character trait of BOD. The 
relationship between ozone dosage and natural fluorescence intensity was 
understood in this study by conducting off-line experiments in the laboratory, 
and thus fluorescence intensity could be recognised as a parameter/index of 
wastewater quality during ozonation. For technicians working in WWTPs, 
off-line experiments measuring fluorescence intensity for ozonated samples 
are feasible, but they are quite time-consuming. Hence, if an online sensor for 
detecting fluorescence intensity could be developed, wastewater quality dur-
ing ozonation could be controlled based real-time data for fluorescence inten-
sity. Furthermore, an optimised dose of ozone, achieving discharge standards 
for BOD, namely a higher ozone dose and less fluorescence intensity. Addi-
tionally, the relationship between fluorescence intensity and pharmaceutical 
concentration in wastewater is also interesting to interpret. If there were a 
coherent relationship, basic concentrations of pharmaceuticals will be able to 
indirectly calculate based on fluorescence intensity, and subsequent tradition-
al analysis of pharmaceuticals could be omitted.  
In this study, the MBBRs were generally run over a year or even more, and 
the effect of temperature on performance of MBBRs can’t omit, especially 
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there is big temperature difference in summer and winter in Denmark. There 
were 5℃ differences in previous operation of MBBRs, which could affect 
performances of MBBRs on removal of pharmaceuticals, reduction of toxici-
ty and fluorescence intensity. Therefore, in future, clear differences regarding 
the above performances in summer and winter need to be understood.  
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